BTG Share PerformanceMore
|52 week high||739.5 12/07/16|
|52 week low||555.0 04/02/16|
|52 week change||-50.5 (-8.19%)|
|4 week volume||14,792,466 09/11/16|
Latest News« previous» nextMore
05/12/2016 - 07:58 StockMarketWire
BTG has announced the inclusion of treatment with PneumRx Coils in guidelines for the management of chronic obstruc...
05/12/2016 - 07:00 RNS
RNS Number: 8933Q BTG PLC 05 December 2016 PneumRx Coils included in new global clinical guidelines and given positive recommendation to treat severe emphysema patients in France London, UK, 5 December 2016: BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with PneumRx Coils in guidelines for t...
01/12/2016 - 13:33 RNS
RNS Number: 7289Q BTG PLC 01 December 2016 1 December 2016 BTG plc - To tal Voting Rights and Share Capital In accordance with FCA's Disclosure and Transparency Rule 5.6.1, BTG plc (the "Company") notifies that as at 1 December 2016: 1. the Company's issued share capital consists of 385,088,997 Ordinaryshares of 10p each admitted to trading, and each with o...
25/11/2016 - 16:58 RNS
RNS Number: 2249Q BTG PLC 25 November 2016 For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii BTG plc 2 Reason for the notification (please tick the appropriate b...
17/11/2016 - 10:10 StockMarketWire
Deutsche Bank today reaffirms its buy investment rating on BTG PLC (LON:BTG) and cut its price target to 800p (from 8...
16/11/2016 - 12:52 Interactive Investor
Diversification is crucial - it's why Stockopedia's Ben Hobson has gathered the best quality and momentum stocks from 10 ...
16/11/2016 - 11:10 StockMarketWire
JP Morgan Cazenove today reaffirms its neutral investment rating on BTG PLC (LON:BTG) and cut its price target to 800...
15/11/2016 - 07:52 StockMarketWire
BTG reports a strong first half performance with double-digit revenue growth. Revenues rose to 285.4m in the six months ...
|Dividend yield||0 %|
Equity Research (BTG)
Growth across all three divisions of BTG’s Interventional Medicine (IM) franchise (oncology, vascular and pulmonology), coupled with currency tailwinds, helped push FY16 revenue towards the upper end...
BTG’s interim results have driven upgrades to our financial forecasts with a small boost to revenues from one-off Zytiga backdated royalties. Our operating expenses are broadly unchanged, but...
BTG’s close period update saw a revision to its FY16 revenue guidance, targeting sales in the lower half of £410-440m (at $1.61/£). This is based on slower-than-expected Varithena sales, despite a...
- 1 of 3
Latest discussion posts More
“Being a gold standard product should help BTG sell it sell it ,how ever ,knowing how B.T.G has moved in the past when marketing products word wide in the past then I'm not ...”▼
“Back in with a long position. This one is a trading dream. Couldn't agree more with UP., this is not the price to sell at. Growth story still intact. M”▼
“Todays RNS is great news & progress in France will hopefully be replicated elsewhere.Not sure what impact,if any ,it will have on our SP.”▼
Codes & Symbols
|Symbols||BTG, LSE:BTG, BTG.L, BTG:LN, LON:BTG, XLON:BTG|